Capricor Therapeutics Inc. (CAPR) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Capricor Therapeutics Inc. (NASDAQ: CAPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $6.38 (-3.77% 1D, market cap $385.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CAPR ranks #711 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CAPR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RZLT (Rezolute Inc. (NV)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $398.5M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
Per CAPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001133869), Capricor Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$105.0M in net income, and -$72.7M in free cash flow against $355.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.38 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CAPR currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.06) and Max Pain ($6.70) forces dealer call-delta covering toward $42.39.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Capricor Therapeutics Inc. (CAPR) dropped -3.77% to $6.38, trading at 9% of its 52-week range ($2.96 – $40.37). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
November brings several closely watched FDA decisions, with Regeneron and its partner Alnylam’s therapy for generalized myasthenia gravis and Roche’s Gazyva for primary membranous nephropathy in the spotlight this week.
Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CAPR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CAPR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Capricor Therapeutics Inc. (CAPR) ranks #711 by composite RQD confidence (34/100, grade E) and #485 by equity capitalization ($385.5M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CAPR at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CAPR
ACTIVE
Capricor Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.77% | $385.5M | Benchmark Subject |
| RZLT Rezolute Inc. (NV) | D- | 38/100 | — | — | -35.0% | -4.13% | $398.5M | /rzlt-vs-capr → |
| AVTX Avalo Therapeutics Inc. | E | 17/100 | — | — | -35.0% | -3.63% | $399.0M | /avtx-vs-capr → |
| EBS Emergent BioSolutions Inc. | D+ | 52/100 | 7.0x | 56.1% | 8.9% | -5.68% | $370.2M | /ebs-vs-capr → |
| RLMD Relmada Therapeutics Inc. | E | 30/100 | — | — | -35.0% | +4.07% | $366.9M | /rlmd-vs-capr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Capricor Therapeutics Inc. (CAPR) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $22.3M , and -100.0% cumulative change since FY2023) , GAAP net income of -$105.0M, operating cash flow of -$69.8M, and free cash flow of -$72.7M (-76.7% YoY). On the balance sheet, CAPR closed FY2025 with $355.9M in total assets against $0 in total debt (Altman Z-Score: 3.38, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$105.0M | -$69.8M | -$72.7M | $355.9M | — |
| FY2024 (FY) | 2024-12-31 | $22.3M | -$40.5M | -$40.0M | -$41.2M | $170.5M | — |
| FY2023 (FY) | 2023-12-31 | $25.2M | -$22.3M | -$25.6M | -$25.6M | — | — |
As of 2026-11-02, Capricor Therapeutics Inc. (NASDAQ: CAPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $6.38 (-3.77% 1D, market cap $385.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CAPR ranks #711 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CAPR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RZLT (Rezolute Inc. (NV)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $398.5M) and AVTX (Avalo Therapeutics Inc.) posts a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).
Per CAPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001133869), Capricor Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$105.0M in net income, and -$72.7M in free cash flow against $355.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CAPR last traded at $6.38 (-3.77% on volume of 3,357,167 shares), positioning the stock -20.84% below its 50-day simple moving average ($8.06) and -69.01% below its 200-day simple moving average ($20.59). Across its 52-week range of $2.96 to $40.37, CAPR sits at the 9.1% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.58 to $7.18).
Why CAPR Stock dropped -3.77% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, CAPR scores 34 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield -18.86%), Whale 13F Flow at 4/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 7/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 12/20 (Altman Z 3.38; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and Whale 13F Flow, which together indicate limited observable sponsorship from insiders and large institutions. The cash-engine pillar reflects negative return on invested capital and negative free-cash-flow yield, meaning the business is not currently generating returns on capital in the source data. The balance-sheet pillar is the strongest relative score, supported by a 3.38 Altman Z-Score, but the Piotroski F-Score of 2/9 signals weak fundamental quality. For a prospective investor, the rating frames the stock as high-risk on the current evidence. Potential upside drivers in the news flow (such as the November FDA decision referenced in the news wire) are event-dependent and are not quantified in the source data, while valuation tradeoffs are difficult to assess because P/E and EPS are unavailable.
Capricor Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.4B. The source data does not specify its products, customers, or revenue model beyond reported revenue figures in the SEC financials. Revenue is reported as $0.0M for FY 2025, $22.3M for FY 2024, and $25.2M for FY 2023.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-108.1M | $-105.0M | N/A | $-72.7M | $287.8M | N/A |
| FY 2024 | $22.3M | $-42.6M | $-40.5M | N/A | $-41.2M | $11.3M | N/A |
| FY 2023 | $25.2M | $-24.1M | $-22.3M | N/A | $-25.6M | N/A | N/A |
Per the SEC financials, operating losses widened from $-24.1M in FY 2023 to $-108.1M in FY 2025, and revenue declined to $0.0M in FY 2025. Gross, operating, and net margins are each reported as 0% in the market data. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 3.38, while the Piotroski F-Score is 2/9 and Debt/Equity is 0.5. Reported cash is $287.8M for FY 2025, compared with $11.3M for FY 2024. The source data does not provide a debt figure for any period.
Per the recent news and catalysts feed, the most prominent items are: a market-wire report of a near-5% stock rise tied to heart data for deramiocel ahead of a November FDA decision; a Seeking Alpha report referencing HOPE-3 open-label extension data for Duchenne muscular dystrophy; a Benzinga report on Monday trading action; a GuruFocus report, flagged as a RISK WATCH item, describing a share drop of 10% despite positive data; a StockInvest.us forecast piece; and a TradingView estimates page. The clearest catalyst identified is the November FDA decision on deramiocel. The RISK WATCH item is the GuruFocus report of a 10% decline. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Capricor Therapeutics Inc. (CAPR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Capricor Therapeutics Inc. (CAPR) market action, institutional positioning, and fundamental catalysts.
Welcome to the CAPR (Capricor Therapeutics Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CAPR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Capricor Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CAPR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.63 (52-wk range $2.96 - $40.37), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).